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Abstract
Background: Sulphadoxine-pyrimethamine has been abandoned as first- or second-line treatment
by most African malaria endemic countries in favour of artemisinin-based combination treatments,
but the drug is still used as intermittent preventive treatment during pregnancy. However,
resistance to sulphadoxine-pyrimethamine has been increasing in the past few years and, although
the link between molecular markers and treatment failure has not been firmly established, at least
for pregnant women, it is important to monitor such markers.
Methods: This paper reports a novel sensitive, semi-quantitative and specific real-time PCR and
melting curve analysis (MCA) assay using fluorescence resonance energy transfer (FRET) for the
detection of DHPS-540, an important predictor for SP resistance. FRET/MCA was evaluated using
78 clinical samples from malaria patients and compared to PCR-RFLP.
Results: Sixty-two samples were in perfect agreement between both assays. One sample showed
a small wild type signal with FRET/MCA that indicates a polyclonal infection. Four samples were
not able to generate enough material in both assays to distinguish mutant from wild-type infection,
six samples gave no signal in PCR-RFLP and five samples gave no amplification in FRET/MCA.
Conclusion: FRET/MCA is an effective tool for the identification of SNPs in drug studies and
epidemiological surveys on resistance markers in general and DHPS-540 mutation in particular.
Background
Malaria control is hampered by increasing spread of drug
resistance [1]. Although sulphadoxine-pyrimethamine
(SP) has been abandoned as first- or second-line treat-
ment by most African malaria endemic countries in
favour of artemisinin-based combination treatments
(ACT), it is still used as intermittent preventive treatment
during pregnancy (IPTp) [2-4]. However, SP resistance has
been on the rise in the past few years and, although the
link between molecular markers and treatment failure has
not been firmly established, at least for pregnant women,
these markers should be monitored. Pyrimethamine
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binds to malarial dihydrofolate reductase (DHFR) and
inhibits its enzymatic activity. Sulphadoxine competes
with a natural substrate of dihydropteorate synthase
(DHPS) and consequently inhibits the enzyme. Resist-
ance to these drugs has been associated with single nucle-
otide polymorphisms (SNP) in the genes encoding DHFR
and DHPS [5-8]. One of the SNPs that is associated with
SP drug resistance is the Lys → Glu substitution in codon
540 of the DHPS gene. Although there is conflicting evi-
dence about the role of the dhps Glu-540 mutation it is
considered a strong predictor for SP treatment failure. In
some studies that describe treatment fialure no DHPS
gene is found but in other studies in for example Uganda
the glu-DHPS mutation was found to be the strongest
independent predictor of treatment failure [8,9]. In addi-
tion they found that other important mutations such as
the dhfr Arg-59 mutation were only predictive of treat-
ment failure in the presence of the dhps Glu-540 mutation
[9].
In most countries chloroquine (CQ) has been, for many
years, the first line drug for malaria treatment. Unfortu-
nately, resistance to this drug is nowadays widespread.
However, in areas where drug pressure has been removed,
the molecular markers linked to CQ drug resistance seem
to disappear [10,11], indicating that local parasites are
again sensitive to this drug. It is, therefore, important to
have the means for monitoring drug resistance and under-
stand its spread as this may be important in design strate-
gies to prevent the selection of drug resistant parasites
[8,12]. The spread of point mutations linked to drug
resistance could be monitored by carrying out regular
cross sectional surveys and then genotyping the samples
from infected people. Molecular tools for the detection
and identification of these SNPs, such as Amplification
Refractory Mutation System PCR (ARMS-PCR) or Restric-
tion Fragment Length Polymorphism PCR (RFLP-PCR),
are available [13,14]. Although RFLP-PCR is widely used
to identify SNPs, it is a time consuming, low throughput
and labour-intensive technique, that is not able to quan-
tify different genotypes in a polyclonal infection and is
prone to DNA contamination [15,16]. Fluorogenic assays
can be a good alternative for the detection of SNP muta-
tions conferring drug resistance [16,17]. PCR in combina-
tion with fluorescence resonance energy transfer (FRET),
which uses two fluorophores that are brought in close
proximity after hybridization, can detect point mutations
in DHFR gene linked to pyrimethamine resistance[18]. In
short, the principle of FRET is as follows: during PCR, a
primer labeled with fluorophore which are called "donor"
hybridizes to the formed amplicon. After PCR, an addi-
tional probe with a fluorophore "the acceptor" is added
tot the reaction and, during denaturation, anneals to the
template. The fluorescence emitted from the donor is then
absorbed by the acceptor, resulting in fluorescence emis-
sion by the acceptor, FRET, which can be detected. When
this reaction is followed by melt curve analysis (MCA),
dissociation of the fluorophores and consequently loss of
FRET signal occurs. This depends on the thermodynamic
stability of the probes, allows the discrimination between
total complementary probe target (wild-type samples)
and mismatched probe target combinations (mutant sam-
ples) (Figure 1) [19].
Schematic representation of FRET assay Figure 1
Schematic representation of FRET assay. Step 1. A 
PCR reaction results in amplification of a 169 bp fragment 
with an incorporated ROX fluorophore attached to the for-
ward primer. Step 2. After amplification, the FAM-labelled 
probe is added to the reaction and during initial denaturation 
hybridizes to the amplicon. Step 3. The two fluorophores are 
now in close proximity of each other and energy from the 
excited donor is transferred to the acceptor generating the 
FRET signal. Step 4. The increase of temperature during melt 
curve analysis leads, at a specific temperature, to the dissoci-
ation of the probe from the amplicon. When the probe is 
dissociated transfer of energy is lost and therefore no FRET 
signal can be observed.Malaria Journal 2008, 7:48 http://www.malariajournal.com/content/7/1/48
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This paper describes a new FRET/MCA assay with a fluor-
ogenic primer/probe design in combination with MCA,
which enables: 1) the identification of the genotype (wild
type or Lys → Glu substitution) in codon 540 of the DHPS
gene of Plasmodium falciparum that is highly associated
with sulphadoxine resistance; 2) the quantification of the
different genotypes in a polyclonal infection.
Materials and methods
Samples
Seventy-eight field samples were obtained in the context
of a larger study, in collaboration with Epicentre (Paris,
France) on the therapeutic effects of anti-malarial drugs
for the treatment of falciparum malaria in the Democratic
Republic of Congo [13]. The samples were collected in
Boende, Kilwa and Kisangani during the malaria transmis-
sion season between September 2003 and March 2004,
after obtaining ethical approval from the national health
authorities and the research ethics committee of Prince
Leopold Institute of Tropical Medicine, Antwerp (ITMA).
The human experimentation guidelines of ITMA were fol-
lowed.
After obtaining informed consent, finger-prick blood
samples were collected at initial diagnosis onto a 3 M
Whatman filter paper and stored at room temperature in
an individual zip-lock polyethylene bag until further DNA
extraction.
Parasitaemia was determined from Giemsa-stained thick
smears by counting the number of parasites against 200
leucocytes assuming that there were 8,000 leucocytes/μl
blood. Plasmids containing a DHPS insert of a known
genotype, i.e. PS-Mali (wild type for codon 540) and PS-
Peru (mutant Lys → Glu substitution), were obtained
from the Malaria Research and Reference Reagent
Resource Center, Division of Microbiology and Infectious
Diseases, NIAID, NIH, deposited by C. Plowe. To deter-
mine the capability of the assay to discriminate between
mixed infections, artificial mixes of these clones were
made in rations of 1:9/9:1. The estimated percentage of
the genotypes in the mixture are represented by the area
underneath the peak for that genotype and automatically
calculated by the intergtrated software.
As a reference, DHPS genotyping for DHPS codon 540
was done by PCR followed by restriction digestion as pre-
viously described [12]. The products were visualized by a
UV light transilluminator after running the products for
three hours at 50 volt on a 3% ethidium bromide stained
agarose gel. PS-Peru and PS-Mali were used as controls.
Primers and probe design
Nested PCR was used to amplify enough bulk template for
optimization with specific primers flanking the codon
540 of the DHPS gene (710 bp); forward primer: 5'-AAC-
CTAAACGTGCTGTTCAA-3'; reverse primer: 5'-AATTGT-
GTGATTTGTCCACAA-3' previously published [12].
Secondary PCR primers amplifying a 169 bp product,
(forward primer: 5'-ATGCATAAAAGAGGAAATACA-
CATAC-3' and reverse primer: 5'-TCATGTTTCTTCG-
CAAATCC-3') were selected based on the absence of
primer dimers, melting temperature, hairpin and second-
ary structure configurations and their GC content and
analysed with Primer3 [20] and DNA mfold [21]. In order
to prevent hairpin formation, a mutation in the forward
primer was introduced. The forward primer was labeled
with an internal 5-carboxy-x-rhodamine (ROX) at the last
thymine (base 24).
All primers were checked for their specificity by a BLAST
search [22].
The fluorogenic probe was designed to have the highest
difference in melting temperature between the wild type
and mutatant strand as calculated by Meltcalc, [23]. The
probe 5'-CATAATTTGTTAGTTTATCCA-3'complements
the wild type antisense strand of the PCR product and was
labeled with 3' 6-carboxyfluorescein (FAM).
FRET-PCR
A primary PCR was performed before starting the FRET/
MCA analysis to increase sensitivity. Each reaction of 25 μl
contained 200 μM MgCl, 200 μM dNTP, 1× reaction
buffer (Promega), 5 U/μl Taq DNA polymerase
(Promega), and 250 nM of forward and reverse primer. To
each reaction 3 μl of template was added. For amplifica-
tion the following protocol was used: 3 min 94°C fol-
lowed by five cycles of 1 min 94°C, 2 min 45°C and 1
min 72°C. This was followed by 35 cycles of 1 min 94°C,
1 min 45°C and 1 min 72°C and a final step of 10 min
72°C.
Following primary amplification a FRET/MCA PCR was
performed. All FRET/MCA assays were performed on a
iCycler (BioRad Hercules, USA) and analysis of the results
was done by iCyclerIQ optical system software version
3.0a (BioRad Lab inc.). Each reaction of 50 μl contained
1× IQsupermix (BioRad laboratories) and the complete
primer/probe set. The target strand to which the probe
binds was produced in excess by an asymmetric PCR con-
taining 500 nmol/L ROX labeled forward and 100 nmol/
L reverse primer. The probe (160 nmol/L) was added
directly after amplification after which the MCA was per-
formed. The total protocol was as follows: 3 min 95°C, 35
cycles of 30 sec 95°C, 1 min 58°C, 1 min 72°C and a final
step of 8 min 72°C.Malaria Journal 2008, 7:48 http://www.malariajournal.com/content/7/1/48
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Melt curve analysis
After amplification the melt curve analysis (MCA) was
performed with a 490/20× FAM excitation filter and a
620/30 M ROX emission filter. Immediately after the PCR,
probe was added starting at 60°C with 60 repeats of heat-
ing for 30 sec with 0.5°C increments. All experiments
were performed in triplicate and in addition to DNA tem-
plate, MilliQ and plasmids PS-Mali and PS-Peru were used
as control samples. Well factor errors were subtracted
from the post run data by using a 96 well optical plate
containing 50 μl 1× external well solution in each well
(BioRad Laboratories) before the actual MCA. These fac-
tors are used by the system to compensate for any pipet-
ting or system inconsistencies in order to optimize the
post-run data analysis.
Statistical analysis
PCR-RFLP for the DHPS-540 identification was consid-
ered as the reference method. All FRET-PCR/MCA results
were compared to the results obtained with the PCR-RFLP
standard. The agreement between PCR-RFLP and the
FRET-PCR/MCA assay was determined by calculating
Kappa statistics values with a 95% confidence interval
[24]. Kappa statistics is measure of agreement between
categorical measurements, in this case the outcome of two
diagnostic tests, in which the accuracy of a test is calcu-
lated. It is thus an index which compares the observed
agreement against that which might be expected by
chance. Kappa can be thought of as the chance-corrected
proportional agreement, and possible values range from
+1 (perfect agreement) via 0 (no agreement above that
expected by chance) to -1 (complete disagreement).
Kappa values of 0.21 – 0.60 is a moderate, a kappa value
of 0.61–0.80 a good and kappa > 0.80 an almost perfect
agreement beyond chance.
Results
Analytical performance of the assay
Predictions made by Meltcalc on the melting temperature
(Tm), resulted in stability calculations of the sequence
with and without mutation of 54.5°C and 51.0°C, respec-
tively. Analysis with MCA on wild type clone PS-Mali
resulted in an average Tm of 55.7°C (n = 15; std = 0.41°C)
and of an average Tm of mutant clone PS-Peru of 51.9°C
(n = 15; std = 0.32°C) (Figure 2). However, when analys-
ing field samples the average Tm for wild type samples
Output file of the MCA assay with plasmid DNA Figure 2
Output file of the MCA assay with plasmid DNA. The figure shows the melt curve analysis of wild type clone PS-Mali in 
triplicate (red curves) resulted in an average Tm of 55.7°C. In green the melt curve profile (in triplicate) of mutant clone PS-
Peru is shown with a Tm of of 51.9°C. The change in amount of fluorescence for each probe-template hybrid was plotted 
against the temperature and its negative derivative appeared as a positive peak. The grey lines represent the negative controles.Malaria Journal 2008, 7:48 http://www.malariajournal.com/content/7/1/48
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was 51.5°C and 55.0°C for the mutant samples (Figure
3).
Artificial mixed infections of PS-Mali and PS-Peru clones
gave observable peaks from mix ratios 2:8 to 8:2, which
were also calculated as such by the software. The ratios 1:9
and 9:1 gave no observable second peak after MCA and
identified the mixes as being a mono infection of either
PS-Mali or PS-Peru.
Analysis of field samples
In total, 78 microscopy positive samples (range: 16 para-
sites/μl – 197400 parasites/μl) were analysed with PCR-
RFLP as well as with FRET/MCA. PCR RFLP obtained a
result in 68 samples. The remaining 10 samples, which
were found positive with microscopy (16–46 parasites/μl)
showed no amplification with PCR-RFLP. FRET/MCA
could classify 69 samples; in the other 9 no MCA results
could be obtained. The samples that were negative with
MCA and or RFLP were all samples that contained very
low parasite numbers as revealed by standard microscopy
(<50 parasites/μl) probably leading to an insufficient tem-
plate amount for PCR. The results of both assays are pre-
sented in Table 1.
In the 15 samples identified as a mixed infection by FRET/
MCA, five samples had an equal amount of both wild type
and mutant parasites. The wild type was dominant in six
samples and four samples had the mutant type as domi-
nant polymorphism. The ratios varied between 30%–70%
mutant/wild type to 70%–30% wild-type/mutant. One
sample showed a mutant infection in PCR-PFLP and a
Table 1: Overview of the mutant, wild type and mixed infections 
of the 78 samples analysed with PCR-RFLP and FRET/MCA.
PCR-RFLP FRET/MCA
WM W / M N / A
W2 7 00 4
M 0 21 10
W/M 00 14 1
N/A 41 1 4
W = wild type; M = mutant, W/M = mixed infection with wild type 
and mutant genotype, N/A = no amplification
Identification of a polyclonal infection Figure 3
Identification of a polyclonal infection. Blood samples from two patients with malaria that have a biclonal infections. The 
MCA curves of these samples with two peaks represented in blue and purple are shown. The sample represented in purple 
contains according to the intergrated software a 45% to 55% ratio of mutant and wild type infection respectively. The sample 
represented in blue shows the opposite pattern and contains 55% to 45% mutant and wild type infection respectively. This can 
also be seen in the figure by the difference in peak hight. The red curves are the positive controls for wild type strains and the 
green for mutant strains. The blue horizontal line represents the threshold for background fluorescence, and the curve entirely 
below shows the results for the negative control (gray).Malaria Journal 2008, 7:48 http://www.malariajournal.com/content/7/1/48
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mixed infection with FRET/MCA with a small wild-type
peak in addition to a dominant mutant peak.
Statistical analysis
A high degree of agreement was observed between the
FRET/MCA assay and PCR/RFLP in the present study for
the identification of mutant or wild-type strains in a sam-
ple. The overall kappa value of 0.7828 (95% CI:
0.6719–0.8937) indicates a good agreement beyond
chance. The kappa for wild type and mutant mutations is
1 (95% CI: 0.9647–1) and the kappa for the identification
of mixed infections is 0.9552 (95% CI: 0.8765–1).
Discussion
Understanding the mechanisms of drug resistance is of
major importance for malaria control. However, good
methods to identify drug resistance markers, monitoring
spread of resistance and the ability to quantify polymor-
phic populations in mixed infections is currently lacking.
In the light of SP resistance on the one hand and the
implementation of IPTp on the other hand, it is becoming
very important to carefully examine the presence of resist-
ance markers in the population [1-3,25]. Molecular tech-
niques such as ARMS-PCR and PCR-RFLP are available for
the detection of different mutations but have disadvan-
tages such as long processing time and the fact that quan-
tification of mixed infections is not possible [13,15,16].
Although real-time PCR assays able to (semi)-quantify are
currently available, they often do not discriminate
between single and polyclonal infections [16,17]. This
paper describes the development of a semi-quantitative
FRET/MCA assay for the detection of SNPs in codon 540
of the DHPS gene of P. falciparum able to detect polyclonal
infections. The FRET/MCA assay has already successfully
been used for the identification of SNPs in several
genomes, including several mutations in the DHFR gene
of P. falciparum [18]. Although this FRET/MCA technique
requires a high initial equipment outlay, consisting of a
standard PCR cycler equipped with an optical module,
and uses expensive reagents such as the flurorophores,
which make this technique three times more expensive (7
euro per assay) than RFLP analysis, it offers several advan-
tages over existing methods. Methods such as sequencing
are also able to identify SNPs, but require purchase and
setting up special sequence facilities and additional sam-
ple preparation reagents and steps. The major advantage
of the FRET/MCA technique is its ability to screen simul-
taneously for mutant as well as wild type specimens in
one reaction with the use of only one probe. In contrast,
two separate enzymatic reactions are required to genotype
the specimens with RFLP analysis. The total handling time
of a RFLP analysis takes around two days whereas a FRET/
MCA analysis can be performed in less than one day. In
addition, the FRET/MCA is designed to run in a 96-well
format with integrated software to analyse the fluores-
cence data which makes analysis compared to for example
sequencing very easy. In the initial development stage,
samples were run in triplicate to verify reproducibility but
the high reproducibility and ease of interpretation allows
up to 90 samples to be analyzed in a single run. Secondly,
if new mutations arise at the probe-amplicon hybrid,
these mutations can simply be detected by the FRET/MCA
assay. RFLP analysis or Q-PCR methods, in contrast, can
only detect resistance that are already known and for
which an assay is available.
This study shows that the developed assay is able to cor-
rectly identify mutant and wild type samples when com-
pared to PCR-RFLP. Mixed infections can readily be
identified with both assays. The assay allows semi-quanti-
tative analysis of the sample and is able to identify the
dominant type in a sample with high throughput. One of
the tested samples identified a sample with a low concen-
tration of wild type parasites whereas the PCR-RFLP iden-
tified this sample as a mutant infection. Although this
would suggest higher sensitivity of the assay there were
some samples with very low number of parasites that were
not able to give a signal. Nevertheless, the assay is as sen-
sitive as PCR-RFLP. When this assay could be combined
with the DHFR assay it would allow the rapid and high
throughput screening of large number of samples.
Conclusion
The developed real-time FRET/MCA for the detection of
single nucleotide polymorphisms in the region of codon
540 of the DHPS gene of P. falciparum is an easy and very
specific technique. The assay can be used for the detection,
identification and semi-quantitative measurement of SNP
not only in single genotype but also mixed genotype pop-
ulations. The sensitivity and specificity of the assay makes
the FRET/MCA an effective tool for the identification of
SNP's in drug studies or epidemiological surveys for the
determination of the prevalence of resistance markers,
more particularly for that of the DHPS-540 mutation.
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